Magnesium chloride: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|authorTag={{Ammu}}
|genericName=magnesium chloride
|aOrAn=a
|aOrAn=a
|drugClass=
|drugClass=electrolyte
|indicationType=
|indicationType=treatment
|indication=
|indication=as an electrolyte replenisher in magnesium deficiencies
|hasBlackBoxWarning=Yes
|adverseReactions=[[flushing]], [[sweating]], sharply lowered blood pressure, [[hypothermia]], [[stupor]], and ultimately respiratory depression.
|adverseReactions=<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 17: Line 15:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=* As an electrolyte replenisher in magnesium deficiencies.
 
* For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage.
* Dosing Information
* USUAL DOSAGE RANGE: 1 to 40 grams daily.
 
* Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
:* Dosage
|offLabelAdultGuideSupport=
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====


There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
Line 74: Line 30:


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.


Line 87: Line 36:


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=* Magnesium Chloride Injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients.
 
|warnings=* Do not use if a precipitate is present.
<!--Warnings-->
* This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
|warnings=* Description
* Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.


=====Body as a Whole=====


 
|postmarketing=* Flushing, [[sweating]], sharply lowered blood pressure, [[hypothermia]], [[stupor]], and ultimately respiratory depression.
 
|FDAPregCat=C
 
|useInPregnancyFDA=* Animal reproduction studies have not been conducted with magnesium chloride. It is also not known whether magnesium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium chloride should be given to a pregnant woman only if clearly needed.
=====Cardiovascular=====
|useInPregnancyAUS=
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|FDAPregCat=
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
Line 270: Line 69:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|administration=


* Intravenous
* Intravenous
Line 281: Line 80:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|drugBox={{chembox2
 
| Verifiedfields = changed
====Signs and Symptoms====
| Watchedfields = changed
 
| verifiedrevid = 459589655
* Description
| ImageFile = Magnesium chloride.jpg
 
| ImageSize = 200px
====Management====
| ImageFile1 = Magnesium-chloride-3D-polyhedra.png
 
| IUPACName = Magnesium chloride
* Description
| SystematicName = Magnesium chloride
 
| OtherNames = Magnesium dichloride
===Chronic Overdose===
| Section1 = {{Chembox Identifiers
 
| Abbreviations =  
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| CASNo = 7786-30-3
 
| CASNo_Ref = {{cascite|correct|CAS}}
<!--Pharmacology-->
| CASOther = <br/>{{CAS|7791-18-6}} (hexahydrate) <!--also verified against the Chemical Abstracts Service list -->
 
| EINECS =  
<!--Drug box 2-->
| EINECSCASNO =
|drugBox=<!--Mechanism of Action-->
| PubChem = 24584
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200547
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 22987
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6636
| SMILES = [Mg+2].[Cl-].[Cl-]
| InChI = InChI=1S/2ClH.Mg/h2*1H;/q;;+2/p-2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/2ClH.Mg/h2*1H;/q;;+2/p-2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = TWRXJAOTZQYOKJ-UHFFFAOYSA-L
| RTECS = OM2975000
| ATCCode_prefix = A12
| ATCCode_suffix = CC01
| ATC_Supplemental = {{ATC|B05|XA11}}
  }}
| Section2 = {{Chembox Properties
| Formula = MgCl<sub>2</sub>
| MolarMass = 95.211 g/mol (anhydrous)<br/>203.31 g/mol (hexahydrate)
| Appearance = white or colourless crystalline solid
| Density = 2.32 g/cm<sup>3</sup> (anhydrous) <br> 1.569 g/cm<sup>3</sup> (hexahydrate)
| MeltingPtC = 714
| Melting_notes = {{convert|117|C|F K}} (hexahydrate) <br> on rapid heating: slow heating leads to decomposition from {{convert|300|C|F K}}
| BoilingPtC = 1412
| Boiling_notes =
| Solubility = ''anhydrous'' 52.9 g/100 mL (0 °C) <br> <br> 54.3 g/100 ml (20&nbsp;°C) <br> 72.6 g/100 mL (100&nbsp;°C) <hr> ''hexahydrate'' <br> 167 g/100 mL (20&nbsp;°C)
| Solubility1 = 7.4 g/100 mL (30&nbsp;°C)
| Solvent1 = ethanol
| SolubleOther = slightly soluble in [[acetone]], [[pyridine]]
| LogP =
| HenryConstant =
| RefractIndex = 1.675 (anhydrous) <br> 1.569 (hexahydrate)
  }}
| Section3 = {{Chembox Structure
| CrystalStruct = [[Cadmium chloride#Crystal structure|CdCl<sub>2</sub>]]
| Coordination = (octahedral, 6-coordinate)
| MolShape =
  }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf = -641.1 kJ/mol
| DeltaGf = -591.6 kJ/mol
| Entropy = 89.88 J/mol K
| HeatCapacity = 71.09 J/mol K
  }}
| Section7 = {{Chembox Hazards
| ExternalMSDS = [http://www.inchem.org/documents/icsc/icsc/eics0764.htm ICSC 0764]
| EUClass =
| EUIndex = Not listed
| MainHazards = Irritant
| NFPA-H = 1
| NFPA-F = 0
| NFPA-R = 0
| NFPA-S =
| RPhrases = {{R36}}, {{R37}}, {{R38}}
| SPhrases = {{S26}}, {{S37}}, {{S39}}
| FlashPt = Non-flammable
| LD50 = 2800 mg/kg (oral, rat)
| PEL =
  }}
| Section8 = {{Chembox Related
| OtherAnions = [[Magnesium fluoride]]<br/>[[Magnesium bromide]]<br/>[[Magnesium iodide]]
| OtherCations = [[Beryllium chloride]]<br/>[[Calcium chloride]]<br/>[[Strontium chloride]]<br/>[[Barium chloride]]<br/>[[Radium chloride]]
| OtherFunctn =
| Function =
| OtherCpds =
  }}
}}
|mechAction=*  
|mechAction=*  


Line 320: Line 187:
<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=*
|storage=
|packLabel=<!--Patient Counseling Information-->
|packLabel=
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Revision as of 03:32, 29 December 2014

Magnesium chloride
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Magnesium chloride is a electrolyte that is FDA approved for the treatment of as an electrolyte replenisher in magnesium deficiencies. Common adverse reactions include flushing, sweating, sharply lowered blood pressure, hypothermia, stupor, and ultimately respiratory depression..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • As an electrolyte replenisher in magnesium deficiencies.
  • For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage.
  • USUAL DOSAGE RANGE: 1 to 40 grams daily.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Magnesium chloride in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Magnesium chloride in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Magnesium chloride in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Magnesium chloride in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Magnesium chloride in pediatric patients.

Contraindications

  • Magnesium Chloride Injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients.

Warnings

  • Do not use if a precipitate is present.
  • This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
  • Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Magnesium chloride in the drug label.

Postmarketing Experience

Drug Interactions

There is limited information regarding Magnesium chloride Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • Animal reproduction studies have not been conducted with magnesium chloride. It is also not known whether magnesium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium chloride should be given to a pregnant woman only if clearly needed.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Magnesium chloride in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Magnesium chloride during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Magnesium chloride with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Magnesium chloride with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Magnesium chloride with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Magnesium chloride with respect to specific gender populations.

Race

There is no FDA guidance on the use of Magnesium chloride with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Magnesium chloride in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Magnesium chloride in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Magnesium chloride in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Magnesium chloride in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Intravenous

Monitoring

There is limited information regarding Monitoring of Magnesium chloride in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Magnesium chloride in the drug label.

Overdosage

There is limited information regarding Magnesium chloride overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox RefractIndexTemplate:Chembox StructureTemplate:Chembox ThermochemistryTemplate:Chembox MainHazardsTemplate:Chembox RPhrasesTemplate:Chembox SPhrasesTemplate:Chembox NFPATemplate:Chembox FlashPtTemplate:Chembox Lethal amounts (set)Template:Chembox OtherAnionsTemplate:Chembox OtherCationsTemplate:Chembox Supplement
Template:Chembox header2 | Magnesium chloride
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
MgCl2
Molar mass 95.211 g/mol (anhydrous)
203.31 g/mol (hexahydrate)
Hazards
Related compounds
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

Structure

File:Magnesium chloride01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Magnesium chloride in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Magnesium chloride in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Magnesium chloride in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Magnesium chloride in the drug label.

How Supplied

Storage

There is limited information regarding Magnesium chloride Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Magnesium chloride |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Magnesium chloride |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Magnesium chloride in the drug label.

Precautions with Alcohol

  • Alcohol-Magnesium chloride interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Magnesium chloride
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Magnesium chloride
 |Label Name=Magnesium chloride11.png

}}

{{#subobject: 

 |Label Page=Magnesium chloride
 |Label Name=Magnesium chloride11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Magnesium_chloride&oldid=1050992"